Multiplex8+ is a cutting-edge diagnostic test for breast cancer (BCa) patients, that uniquely predicts treatment efficacy across multiple therapeutic approaches, including chemotherapy, immunotherapy, and antibody drug conjugates (ADCs). By identifying a broad spectrum of biomarkers, Multiplex8+ enables highly personalized treatment recommendations.
Together, these features make Multiplex8+ a promising tool for identifying the most effective and personalized treatment options for every BCa patient.
Each report is explained and tailored to the unique clinical parameters of the patient enabling true personalized diagnostics and medicine.
The gene expression of the 4 main BC biomarkers is quantified and crossvalidated by 2 independent methods for exceptional precision and 93% accuracy.
Classification of the tumor into one of the 4 molecular subtypes and 6 TNBC subtypes provides the deepest insights into tumor biology.
By profiling 20,000 genes and 100+ gene signatures, Multiplex8+ predicts sensitivity to treatments (e.g., ADCs), risk of recurrence, and characterizes activity of the major cancer hallmark pathways.
The report provides an unambiguous diagnostic information and a foundation for treatment decisions fostering confidence for patients and medical professionals.
An innovative and efficient BC diagnostics tool with the utmost precision and broad potential.
So far, we provided research-use only test for 64 patients, who comprised all treatment settings and molecular subtypes. For more details on our innovative mFISHseq platform , including findings on tumor profiling, immunotherapy response, and targeted therapies, please explore our manuscript "The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer," published in Nature Communications.
Deployment of Multiplex8+ as a research-use only (RUO) test. (a) Table outlining the number of genes and gene signatures and their relevant drug targets/pathways that were used for clinical testing. (b) Proportion of 64 patients according to treatment setting (left bar), molecular subtype (middle bar), and TNBC subtype (right bar). (c) Frequency of therapies that were recommended as the top 3 according to expression of genes and gene signatures tailored to each of the 64 patients. (d-h) Expression of 20 ADC antigen targets (d), targets relevant to payloads for topoisomerase and microtubule inhibitors (e), endocytosis targets involved in internalization of ADCs (f), lysosome targets involved in degrading antibodies and linkers (g), and targets that confer resistance to ADCs (h). (i) Combinations of these ADC-processing gene targets and signatures can be used to identify patients that are more likely to respond to ADCs like Trodelvy (SG) (Patient 1), Enhertu (T-DXd) (Patient 18), and Trodelvy, Enhertu and Kadcyla (T-DM1) (Patient 15), or those who are less likely to respond because they lack ADC-predictive biomarkers (Patient 23).
Physicians will receive a personalized report that provides a guide for a tailored treatment plan.
Number of patients:
64
To order, please fill out our order form signed by your physician, and contact us at diagnostics@multiplexdx.com
We are dedicated to supporting you throughout the ordering process for our innovative breast cancer diagnostic test Multiplex8+. Our team is committed to providing guidance and assistance to ensure a seamless experience with our test. However, it‘s crucial to understand that our support is intended solely to facilitate the ordering procedure and provide information regarding our diagnostic test. Decisions made regarding medical procedures and results interpretation should be discussed with your healthcare provider.
We are honored to be part of your healthcare journey and strive to make this process as informative and efficient as possible.
| Send Message to |
diagnostics@multiplexdx.com |
| or call |
+421 947 904 001 |
MultiplexDX is one of the most innovative biotech companies, headquartered in Bratislava, Slovakia, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. It was founded in 2016 by Dr. Pavol Cekan who has extensive experience in the fields of biotechnology research in EU and US ecosystems. The company operates in the Science Park of Comenius University and has a dedicated international team of 30 people, complemented by the expertise of our top-level advisory board consisting of world-renowned 2 scientific and 2 business advisors. MDX has achieved remarkable success since its foundation. The company has received numerous awards. It was also recognized as one of the 2017 New Europe 100 Challengers by the Financial Times, Google, and Visegrad Fund. MDX‘s journey includes participation in top-tier accelerators such as the Health Hub Vienna Acceleration Program for biotech start-ups and membership in the Oslo Cancer Cluster. In 2019, MDX became the first SK company in history to be awarded the prestigious EIC Accelerator in which it successfully validated its innovative technology in a large-scale retrospective validation on 1,080 breast tumors. In 2022, MDX achieved a significant milestone by ranking 1st in the TOP3 of the Deloitte Fast 50 CEE. In 2023, the company diagnosed the first 26 patients with breast cancer and signed 4 MoUs with oncology institutes in SK and others in process. In 2023 MDX was chosen, among only 47 EU companies and only 10 SMEs, to be part of the Global Gateway Business Advisory Group to assist the European Commission.
Declaration: MultiplexDX, s.r.o. declares that the Multiplex8+ test is only manufactured and used in MultiplexDX, s.r.o. and meet the applicable general safety and performance requirements (GSPR) of the in vitro diagnostic medical devices Regulation (EU 2017/746). / Declaration.pdf
